Jazz Symposium

Jazz supported Industry Lunch Symposium (Hall A)
Friday, September 20th

Driving a change in outcomes for high-risk AML* and hepatic veno-occlusive disease
Chair: Dr Rafael Duarte, Spain

10:45 Welcome and introduction
Dr Rafael Duarte, Spain
10:50 Driving change in outcomes for high-risk AML*
*High-risk AML defined as therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC)
Prof. Thomas Cluzeau, France
11:10 Q&A
11:20 Surviving severe hepatic VOD: real-world evidence and new data
Dr Rafael Duarte, Spain
11:40 Best practice in action in severe hepatic VOD
Prof. José Pérez-Simón, Spain
12:00 Q&A
12:10 Summary and close
Dr Rafael Duarte, Spain

This symposium is funded and organised by Jazz Pharmaceuticals.
This symposium will contain promotional content and prescribing information will be available upon request and at the Jazz Pharmaceuticals exhibition stand.

Adverse events should be reported. Healthcare professionals are asked to report any suspected adverse events via their national reporting system.
In the United Kingdom: Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/
Adverse events should also be reported to Jazz Pharmaceuticals at
AEreporting@jazzpharma.com or by fax to +44 (0) 1865 598765